Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 InfectionSorana Segal‐Maurer, Jean‐Michel Molina, Edwin DeJesus et al.|New England Journal of Medicine|2022Cited by 312
Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and SpainDeanna Kerrigan, Miranda Murray, Cynthia Brinson et al.|PLoS ONE|2018Cited by 179
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trialOnyema Ogbuagu, Hui Wang, Nicolas Margot et al.|The Lancet HIV|2023Cited by 71